Artivion (NYSE:AORT) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $58.00 price target on the stock.
Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting [Yahoo! Finance]
Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting
Artivion (AORT) Valuation Check After Recent Share Price Moves And Growth Outlook [Yahoo! Finance]
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results